In part 6 of this Exclusive Interview, John Buse compares the Observe 4D study to other similar studies in a conversation with Diabetes in Control Publisher Steve Freed.

In part 7 of this Exclusive Interview, John Buse urges other medical professionals to weigh the risks and benefits of using SGLT in a conversation with Diabetes in Control Publisher Steve Freed.

In part 8, the conclusion of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the good and bad effects of using SGLT2 for patients who have type 1.

HbA1c used less frequently but results in more abnormal results, more diagnoses of prediabetes, diabetes